Abstract 5370
Background
Pan FGFR inhibitors such as Erdafitinib are approved in patients with advanced urothelial carcinoma (aUC) harboring FGFR alterations. Based on the necessity of sensitive and reproducible identification of these alterations in diagnostic routines this study aimed to compare different RNA isolation techniques and the QIAGEN therascreen® FGFR RGQ RT-PCR Kit with the SNaPshot mutational analysis.
Methods
Nucleic acids were extracted from 47 UC patients using the QIAGEN RNeasy® DSP FFPE Kit, STRATIFYER Xtract or Maxwell RNA (Promega) isolation kit. Mutations of the FGFR3 gene were detected using the SNaPshot method as well as via the QIAGEN therascreen® FGFR RGQ RT-PCR Kit. Intrinsic molecular subtypes were assessed using immunohistochemistry (IHC) of GATA3, FOXA1, CK20, CK5 and CD44 as well as RT-qPCR for gene expression of CK20 and CK5.
Results
All three different RNA isolation kits showed comparable amount of extracted RNA (Median 290, 177 and 226 ng/ul). Six hotspot FGFR3 mutations were identified with 100% concordance. The main difference were the necessary working hours: per 10 samples, 4 vs. 4.5 vs 8 hours were needed for Stratifyer, Maxwell or QIAGEN RNA isolation. In addition, of 47 analyzed samples 100% concordance between QIAGEN therascreen® FGFR RGQ RT-PCR Kit and SNapShot analysis were achieved with 18 mutations identified (14 S249C, 2 R248C and 2 Y375). Immunohistochemical basal marker profile (CD44 and CK5) as well as high CK5 expression was observed in 28 (6/28 FGFR3-altered). Luminal marker profile (IHC markers: GATA3, FOXA1 and CK20 as well as expression of CK20) was detected in 37 samples (5/37 with FGFR3 alteration, n.s.).
Conclusions
Different RNA extraction methods presented with comparable amount of nucleic acids with variant working hours. Moreover, a 100% concordance between the well established SNaPshot analysis compared to the QIAGEN therascreen® FGFR RGQ RT-PCR Kit for FGFR3 mutations was observed. So far, the frequency of FGFR3 mutations in aUC was not related to the type of UC as defined by marker profils.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BRIDGE consortium.
Funding
Janssen.
Disclosure
R. Wirtz: Officer / Board of Directors: Stratifyer. M. Eckstein: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Janssen. A. Hartmann: Advisory / Consultancy: Janssen. All other authors have declared no conflicts of interest.
Resources from the same session
2927 - Singapore Caregiver Quality Of Life Scale (SCQOLS): Turkish Validity and Reliability Study
Presenter: Nur Basak
Session: Poster Display session 3
Resources:
Abstract
5066 - Screening for Psicosocial Distress in recently diagnosed cancer patients
Presenter: Eva Baillès
Session: Poster Display session 3
Resources:
Abstract
6074 - Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a Primary Care Center.
Presenter: Begona Grana Suarez
Session: Poster Display session 3
Resources:
Abstract
5129 - The adhesion in the screening measures in carrying patients of breast cancer and ovary hereditary and the relationship with the psychological aspects
Presenter: Melinda Concepcion
Session: Poster Display session 3
Resources:
Abstract
5635 - Assessment of emotional discomfort of oncological patients in the first nursing visit at Donostia University Hospital
Presenter: Elena Uranga
Session: Poster Display session 3
Resources:
Abstract
858 - A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer
Presenter: Hui Hui Sun
Session: Poster Display session 3
Resources:
Abstract
4475 - Pharmacist and Nurse (PN) Led Melanoma Immunotherapy Clinic: Patient Experience Survey
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
1871 - Phone Triage & Acute Review Clinics: The emerging role of the Oncology Specialist Nurse
Presenter: Fiona Barrett
Session: Poster Display session 3
Resources:
Abstract
5193 - Patient reported outcomes during immunotherapy: symptom burden in daily clinical practice
Presenter: José Koldenhof
Session: Poster Display session 3
Resources:
Abstract
2453 - Factors related to hospital length of stay, re-admissions and unplanned care for patients with cancer, an on-going study
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract